HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY

被引：0
|
作者：
Cortelazzo, S. [1 ]
Martelli, M. [2 ]
Ladetto, M. [3 ]
Ferrero, S. [4 ]
Ciccone, G. [5 ]
Evangelista, A. [5 ]
Mian, M. [6 ]
Di Rocco, A. [2 ]
Chiappella, A. [7 ]
Rossi, G. [8 ]
Re, A. [9 ]
Zinzani, P. L. [10 ]
Balzarotti, M. [11 ]
Cavallo, F. [4 ]
Rusconi, C. [12 ]
Gotti, M. [13 ]
Arcaini, L. [13 ]
Gobbi, M. [14 ]
Gomes, M. [15 ]
Molinari, A. [16 ]
Liberati, A. M. [17 ]
Michieli, M. [18 ]
Latte, G. [19 ,20 ]
Cabras, M. G. [21 ]
Novero, D. [22 ]
Paulli, M. [23 ]
Zamo, A. [24 ,25 ]
Chilosi, M. [24 ,25 ]
Federico, M. [26 ]
Vitolo, U. [7 ]
机构：
[1] Ist Clin Humanitas Gavazzeni, Unita Oncol Med & Ematol, Hematol, Bergamo, Italy
[2] Univ Roma La Sapienza, Dip Biotecnol Cellulari & Ematol, Hematol, I-00185 Rome, Italy
[3] AO SS Antonio & Biagio, SC Ematol, Hermatol, Alessandria, Italy
[4] SCDU Ematol Univ, AO Citta Salute & Sci, Hematol, Turin, Italy
[5] AO Citta Salute & Sci, CPO Piemonte Ctr Riferimento Epidemiol & Prevenz, Epidemiol, Turin, Italy
[6] Med Univ Innsbruck, Dept Hematol & Oncol, Hematol, A-6020 Innsbruck, Austria
[7] AO Citta Salute & Sci, SC Ematol, Hematol, Turin, Italy
[8] Spedali Civil Brescia, SC Ematol, Hematol, I-25125 Brescia, Italy
[9] Spedali Civil Brescia, SC Ematol, Hermatol, I-25125 Brescia, Italy
[10] St Orsola Marcello Malpighi Hosp, Ist Ematol & Oncol Med Seragnoli, Hematol, Bologna, Italy
[11] Ist Clin Human, Hematol Oncol Med & Ematol, Rozzano, Italy
[12] Osped Maggiore Niguarda, Div Ematol, Hematol, Milan, Italy
[13] Fdn IRCCS Policlin San Matteo, Dipartimento Ematol Oncol, Hematol, Pavia, Italy
[14] IRCCS AOU San Martino IST, Clin Ematol, Hematol, Genoa, Italy
[15] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Hematol, Lisbon, Portugal
[16] Osped Infermi, UO Ematol, Hematol, Rimini, Italy
[17] Osped Santa Maria, Struttura Complessa Oncoematol, Hematol, Terni, Italy
[18] Med A Ctr Riferimento Oncol, Oncol, Aviano, Italy
[19] UOC Ematol, Hematol, Nuoro, Italy
[20] CTMO Presidio Osped S Francesco, Nuoro, Italy
[21] Osped Businco, Div Ematol, Hematol, Cagliari, Italy
[22] AO Citta Salute & Sci, Anat Patol, Pathol, Turin, Italy
[23] Dipartimento Sci Pediat & Patol Umana, Sez Anat Patol, Pathol, Pavia, Italy
[24] Univ Verona, Dipartimento Patol & Diagnost, Pathol, I-37100 Verona, Italy
[25] AOUI Verona, Verona, Italy
[26] Univ Modena & Reggio Emilia, Policlin, COM Ctr Oncol Modenese, Oncol,Dipartimento Oncol & Ematol, Modena, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S106
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) trial
    Jerkeman, M.
    Kolstad, A.
    Laurell, A.
    Raty, R.
    Gnonbaek, K.
    Geisler, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial
    Genuardi, Elisa
    Romano, Greta
    Beccuti, Marco
    Alessandria, Beatrice
    Mannina, Donato
    Califano, Catello
    Rota Scalabrini, Delia
    Cortelazzo, Sergio
    Ladetto, Marco
    Ferrero, Simone
    Calogero, Raffaele A.
    Cordero, Francesca
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (02) : 378 - 381
  • [23] Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial
    Ribrag, Vincent
    Safar, Violaine
    Kluin-Nelemans, Hanneke
    Oberic, Lucie
    Feugier, Pierre
    Casasnovas, Olivier
    Thieblemont, Catherine
    Daguindau, Nicolas
    Damaj, Gandhi Laurent
    Klapper, Wolfram
    Hoster, Eva
    von Weikersthal, Ludwig Fischer
    Haenel, Mathias
    Andre, Marc
    da Silva, Maria Gomes
    Carcinero, Fernando
    Marin-Niebla, Ana
    Taszner, Michal
    Walewski, Jan
    Boersma, Rinske
    Houtenbos, Ilse
    Delfau-Larue, Marie-Helene
    Le Gouill, Steven
    Dreyling, Martin H.
    BLOOD, 2021, 138
  • [24] IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA (MCL): RESULTS OF THE PHASE II IMCL-2015 GELTAMO TRIAL
    Gine, Soca E.
    De la Cruz, Vicente F.
    Jimenez, Ubieto A.
    Lopez, Jimenez J.
    Martin, Garcia-Sancho A.
    Terol, Castera M. J.
    Gonzalez, Barca E.
    De la Fuente, Burguera A.
    Casanova, Espinosa
    Marin-Niebla, A.
    Muntanola, Prat Ana
    Gonzalez, Lopez T. J.
    Aymerich, Gregorio M.
    Setoain, Perego X.
    Cortes-Romera, M.
    Rotger, Regi A.
    Medina, Herrera A.
    Garcia-Sanz, R.
    Campo, Guerri E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2020, 105 : 93 - 94
  • [25] Rituximab-Lenalidomide (R2) Maintenance Is Superior to Rituximab Maintenance After First- Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 9 - 9
  • [26] Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406)
    Ogura, Michinori
    Tobinai, Kensei
    Shibata, Taro
    Ando, Kiyoshi
    Kurosawa, Mitsutoshi
    Gomyo, Hiroshi
    Uike, Naokuni
    Tsukamoto, Norifumi
    Fukuhara, Noriko
    Shimoyama, Tatsu
    Taniwaki, Masafumi
    Nosaka, Kisato
    Matsuno, Yoshihiro
    Hotta, Tomomitsu
    Tsukasaki, Kunihiro
    Morishima, Yasuo
    Yamamoto, Kazuhito
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia
    Gomez-Almaguer, David
    Tarin-Arzaga, Luz C.
    Moreno-Jaime, Brizio
    Jaime-Perez, Jose C.
    Ceballos-Lopez, Adrian A.
    Ruiz-Argueelles, Guillermo J.
    Ruiz-Delgado, Guillermo J.
    Cantu-Rodriguez, Olga
    Gutierrez-Aguirre, Cesar H.
    BLOOD, 2012, 120 (21)
  • [28] Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with immune thrombocytopenia
    Aydin, Kaniye
    Gurkan, Emel
    CUKUROVA MEDICAL JOURNAL, 2022, 47 (02): : 715 - 721
  • [29] Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial
    Jain, Preetesh
    Young, Chi
    Nastoupil, Loretta J.
    Westin, Jason
    Hill, Holly A.
    Nair, Ranjit
    Iyer, Swami P.
    Fetooh, Ahmed
    Lee, Hun Ju
    Ahmed, Sairah
    Kanagal-Shamanna, Rashmi
    Jelloul, Fatima Z.
    Castillo, Luis Enrique Malpica
    Liu, Yang
    Li, Yijing
    Vargas, Jovanny
    Feng, Lei
    Badillo, Maria
    Thirumurthi, Selvi
    Xu, Guofan
    Deswal, Anita
    Iliescu, Cezar
    Nguyen, Vinh Quang
    Tang, Guilin
    Patel, Keyur P.
    Vega, Francisco
    Medeiros, L. Jeffrey
    Wang, Michael L.
    Flowers, Christopher R.
    BLOOD, 2023, 142
  • [30] RITUXIMAB PLUS HYPERCVAD ALTERNATING WITH HIGH DOSE METHOTREXATE AND CYTARABINE (R-HCVAD) FOR PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL). A MULTICENTER TRIAL FROM GISL
    Merli, F.
    Luminari, S.
    Ilariucci, F.
    Visco, C.
    Ambrosetti, A.
    Stelitano, C.
    Petrini, M.
    Di Renzo, N.
    Angrilli, F.
    Carella, A. M.
    Barbolini, E.
    Federico, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 162 - 162
12345